Roth Capital Issues Pessimistic Outlook for Accuray Earnings

Key Points

• Roth Capital revised down its Q1 2026 earnings estimate for Accuray to ($0.08) per share, reflecting a significant drop from the previous estimate of ($0.03).
• Accuray reported earnings of $0.01 per share for the recently concluded quarter, which was below the consensus estimate of $0.03, and recorded revenues of $127.54 million.
• Major research institutions are adjusting their ratings on Accuray, with Wall Street Zen downgrading its rating to "hold" while BTIG Research maintains a "buy" rating with an increased price target of $5.00.

Accuray Incorporated (NASDAQ:ARAY - Free Report) - Equities researchers at Roth Capital lowered their Q1 2026 earnings per share (EPS) estimates for shares of Accuray in a research note issued on Wednesday, August 13th. Roth Capital analyst J. Wittes now anticipates that the medical equipment provider will post earnings per share of ($0.08) for the quarter, down from their previous forecast of ($0.03). The consensus estimate for Accuray's current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray's Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.05 EPS, FY2026 earnings at ($0.02) EPS and FY2027 earnings at $0.01 EPS.

Several other research analysts also recently commented on the company. Wall Street Zen downgraded Accuray from a "buy" rating to a "hold" rating in a research report on Saturday, August 16th. BTIG Research increased their price objective on shares of Accuray from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Accuray has a consensus rating of "Buy" and a consensus target price of $5.00.

Accuray Stock Performance

Shares of NASDAQ:ARAY traded up $0.0550 during trading on Monday, reaching $1.5650. The stock had a trading volume of 316,365 shares, compared to its average volume of 773,506. The company has a quick ratio of 0.92, a current ratio of 1.64 and a debt-to-equity ratio of 3.35. The stock has a fifty day simple moving average of $1.36 and a two-hundred day simple moving average of $1.61. The firm has a market capitalization of $176.29 million, a price-to-earnings ratio of -78.25 and a beta of 1.24. Accuray has a 52 week low of $1.1401 and a 52 week high of $2.95.

Accuray (NASDAQ:ARAY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). Accuray had a negative net margin of 0.35% and a negative return on equity of 5.79%. The business had revenue of $127.54 million for the quarter, compared to analyst estimates of $123.78 million. Accuray has set its FY 2026 guidance at EPS.

Institutional Trading of Accuray

Hedge funds have recently modified their holdings of the business. Gabelli Funds LLC raised its stake in Accuray by 12.5% during the fourth quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider's stock valued at $89,000 after purchasing an additional 5,000 shares in the last quarter. Geode Capital Management LLC grew its stake in Accuray by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 2,186,154 shares of the medical equipment provider's stock valued at $4,329,000 after purchasing an additional 6,758 shares during the last quarter. Northern Trust Corp grew its position in shares of Accuray by 0.9% in the 4th quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider's stock worth $1,603,000 after buying an additional 7,399 shares during the last quarter. ProShare Advisors LLC boosted its holdings in shares of Accuray by 50.7% in the 4th quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider's stock valued at $54,000 after acquiring an additional 9,187 shares during the last quarter. Finally, North Star Investment Management Corp. boosted its holdings in shares of Accuray by 1.0% in the 1st quarter. North Star Investment Management Corp. now owns 1,058,545 shares of the medical equipment provider's stock valued at $1,895,000 after acquiring an additional 10,000 shares during the last quarter. Institutional investors own 64.08% of the company's stock.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.